跳转至内容
Merck
CN

SML2989

OSMI-2

≥98% (HPLC)

别名:

(R)-Methyl 2-(2-(2-methoxyphenyl)-2-(2-oxo-1,2-dihydroquinoline-6-sulfonamido)-N-(thiophen-2-ylmethyl)acetamido)acetate, OSMI 2, OSMI2

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C26H25N3O7S2
化学文摘社编号:
分子量:
555.62
UNSPSC Code:
12352200
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

OSMI-2, ≥98% (HPLC)

SMILES string

O=C(N1)C=CC2=C1C=CC(S(N[C@@H](C(N(CC3=CC=CS3)CC(OC)=O)=O)C4=C(C=CC=C4)OC)(=O)=O)=C2

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -175.0 to -135.0°, c = 1.0 in chloroform-d

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Quality Level

Biochem/physiol Actions

Cell-permeable precursor of an active-site O-GlcNAc transferase (OGT) inhibitor that effectively downregulates cellular protein O-GlcNAc level.
OSMI-2 is a cell-permeable precursor of an active site-targeting (Kd = 140 nM) O-GlcNAc transferase (OGT) inhibitor. Upon cell entry, OSMI-2 is activated by cellular esterase to the active inhibitor that effectively downregulates cellular protein O-GlcNAc level (20-40 μM for 4 h/HCT116, 50 μM for 24 h/HEK293T) and renders LNCaP prostate cancer cells dependent on CDK9 for growth (confluency post 96-hr treatment = 73% with 40 μM OSMI-2, 56% with 0.5 μM AT7519, 19% with co-treatment; control cells at 20% and 81% at 0 and 96 hr, respectively).

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sara E S Martin et al.
Journal of the American Chemical Society, 140(42), 13542-13545 (2018-10-05)
Reversible glycosylation of nuclear and cytoplasmic proteins is an important regulatory mechanism across metazoans. One enzyme, O-linked N-acetylglucosamine transferase (OGT), is responsible for all nucleocytoplasmic glycosylation and there is a well-known need for potent, cell-permeable inhibitors to interrogate OGT function.
Harri M Itkonen et al.
Molecular cancer research : MCR, 18(10), 1512-1521 (2020-07-03)
O-GlcNAc transferase (OGT) is a nutrient-sensitive glycosyltransferase that is overexpressed in prostate cancer, the most common cancer in males. We recently developed a specific and potent inhibitor targeting this enzyme, and here, we report a synthetic lethality screen using this
Zhi-Wei Tan et al.
Nucleic acids research, 48(10), 5656-5669 (2020-04-25)
Intron detention in precursor RNAs serves to regulate expression of a substantial fraction of genes in eukaryotic genomes. How detained intron (DI) splicing is controlled is poorly understood. Here, we show that a ubiquitous post-translational modification called O-GlcNAc, which is
Harri M Itkonen et al.
Theranostics, 9(8), 2183-2197 (2019-06-01)
O-GlcNAc transferase (OGT) is overexpressed in aggressive prostate cancer. OGT modifies intra-cellular proteins via single sugar conjugation (O-GlcNAcylation) to alter their activity. We recently discovered the first fast-acting OGT inhibitor OSMI-2. Here, we probe the stability and function of the

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持